open access

Vol 6, No 5 (2010)
Review paper
Published online: 2011-01-19
Get Citation

Direct EGFR inhibition imaging in tageted treatment in neoplastic diseases

Marcin Rylski, Jerzy Walecki
Onkol. Prak. Klin 2010;6(5):278-282.

open access

Vol 6, No 5 (2010)
REVIEW ARTICLES
Published online: 2011-01-19

Abstract

Epidermal growth factor receptor (EGFR) targeted therapy is a novel pharmacological approach to a treatment of neoplastic diseases in humans. In a clinical practice treatment results are currently monitored in vivo using indirect (not targeted to EGFR) imaging strategies, like computed tomography, ultrasound or classical magnetic resonance imaging. However, methods dedicated for direct EGFR imaging and based on positron emission tomography are already at the preclinical stage of development. In the paper, most important data related to direct EGFR expression imaging in neoplasms was reviewed.

Onkol. Prak. Klin. 2010; 6, 5: 278–282

Abstract

Epidermal growth factor receptor (EGFR) targeted therapy is a novel pharmacological approach to a treatment of neoplastic diseases in humans. In a clinical practice treatment results are currently monitored in vivo using indirect (not targeted to EGFR) imaging strategies, like computed tomography, ultrasound or classical magnetic resonance imaging. However, methods dedicated for direct EGFR imaging and based on positron emission tomography are already at the preclinical stage of development. In the paper, most important data related to direct EGFR expression imaging in neoplasms was reviewed.

Onkol. Prak. Klin. 2010; 6, 5: 278–282

Get Citation

Keywords

EGFR; EGF; imaging; PET; targeted therapy; cancer disease

About this article
Title

Direct EGFR inhibition imaging in tageted treatment in neoplastic diseases

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 5 (2010)

Article type

Review paper

Pages

278-282

Published online

2011-01-19

Bibliographic record

Onkol. Prak. Klin 2010;6(5):278-282.

Keywords

EGFR
EGF
imaging
PET
targeted therapy
cancer disease

Authors

Marcin Rylski
Jerzy Walecki

References (28)
  1. Pantaleo MA, Nannini M, Maleddu A, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009; 20(2): 213–226.
  2. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002; 110(6): 669–672.
  3. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183–232.
  4. Sharma S, Bell D, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer. 2007; 7(3): 169–181.
  5. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11): 1160–1174.
  6. Mishani E, Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med. 2009; 50(8): 1199–1202.
  7. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8): 786–792.
  8. Yu HA, Arcila ME, Rekhtman N, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3): e73.
  9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.
  10. Chung KiY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23(9): 1803–1810.
  11. Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006; 6(11): 1539–1552.
  12. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010; 277(2): 301–308.
  13. Mishani E, Abourbeh G. Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem. 2007; 7(18): 1755–1772.
  14. Gelovani JG. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev. 2008; 27(4): 645–653.
  15. Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging. 2008; 35(1): 186–208.
  16. Mishani E, Abourbeh G, Eiblmaier M, et al. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des. 2008; 14(28): 2983–2998.
  17. Velikyan I, Sundberg AL, Lindhe O, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med. 2005; 46(11): 1881–1888.
  18. Memon AA, Jakobsen S, Dagnaes-Hansen F, et al. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009; 69(3): 873–878.
  19. Liu N, Li M, Li X, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med. 2009; 50(2): 303–308.
  20. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem. 2006; 75: 93–109.
  21. Tolmachev V, Friedman M, Sandström M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med. 2009; 50(2): 274–283.
  22. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004; 22(6): 701–706.
  23. Smith-Jones PM, Solit D, Afroze F, et al. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006; 47(5): 793–796.
  24. Ortu G, Ben-David I, Rozen Y, et al. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer. 2002; 101(4): 360–370.
  25. Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. 2006; 8(5): 262–277.
  26. Abourbeh G, Dissoki S, Jacobson O, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007; 34(1): 55–70.
  27. Su H, Seimbille Y, Ferl GZ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008; 35(6): 1089–1099.
  28. Rylski M, Walecki J. Magnetic resonance imaging at the cellular and molecular levels. . In: Walecki J. ed. Progress in Neuroradiology . International Scientific Literature, Inc., New York 2009.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl